Repositioning Candidate Details
| Candidate ID: | R0826 |
| Source ID: | DB05518 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Managlinat dialanetil |
| Synonyms: | Managlinat dialanetil |
| Molecular Formula: | C21H33N4O6PS |
| SMILES: | [H][C@@](C)(NP(=O)(N[C@@]([H])(C)C(=O)OCC)C1=CC=C(O1)C1=C(CC(C)C)SC(N)=N1)C(=O)OCC |
| Structure: |
|
| DrugBank Description: | CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis. |
| CAS Number: | 280782-97-0 |
| Molecular Weight: | 500.55 |
| DrugBank Indication: | Investigated for use/treatment in diabetes mellitus type 2. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | In type 2 diabetes, the liver produces excessive amounts of glucose through the gluconeogenesis (GNG) pathway and consequently is partly responsible for the elevated glucose levels characteristic of the disease. CS-917 targets the AMP binding site of fructose 1,6-bisphosphatase (FBPase), inhibiting the GNC pathway. |
| Targets: | Fructose-1,6-bisphosphatase 1 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |